MarketsUnichem Laboratories Limited UNICHEMLAB
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
Daily technical summary
Calculated in the browser from validated historical candles. This is descriptive research, not a buy or sell recommendation.
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 3,737.44 | 3,569.4 | 3,274.95 |
| Accumulated Depreciation Total | -759.26 | -685.93 | -585.96 |
| Other Liabilities Total | 29.06 | 40.84 | 36.67 |
| Accrued Expenses | 22.16 | 17.9 | 22.58 |
| Long Term Debt | 39.12 | 60.81 | 38.22 |
| Common Stock Total | 14.08 | 14.08 | 14.08 |
| Other Equity Total | -0.15 | -14.73 | -7.76 |
| Other Current Assets Total | 0.58 | 0.94 | 1.29 |
| Prepaid Expenses | 23.86 | 22.12 | 21.13 |
| Total Assets | 3,737.44 | 3,569.4 | 3,274.95 |
| Current Portof LT Debt/Capital Leases | 19.59 | 33.48 | 29.87 |
| Additional Paid-In Capital | 1.33 | 1.33 | 1.33 |
| Cash | 68.8 | 26.41 | 28.02 |
| Total Equity | 2,717.44 | 2,450.59 | 2,438.3 |
| Long Term Investments | 8.61 | 8.29 | 5.93 |
| Retained Earnings(Accumulated Deficit) | 2,687.48 | 2,435.21 | 2,386.45 |
| Total Common Shares Outstanding | 7.04 | 7.04 | 7.04 |
| Property/Plant/Equipment Total-Gross | 2,063.1 | 1,995.92 | 1,903.16 |
| Tangible Book Valueper Share Common Eq | 384.71 | 345.19 | 338.1 |
| Goodwill Net | 1.55 | 1.55 | 1.55 |
| Total Liabilities | 1,020 | 1,118.81 | 836.65 |
| Total Debt | 500.15 | 459.77 | 247.52 |
| Short Term Investments | 225.32 | 89.49 | 130.19 |
| Cashand Short Term Investments | 294.12 | 116.69 | 158.21 |
| Total Receivables Net | 897.81 | 896.49 | 818.41 |
| Notes Payable/Short Term Debt | 415.44 | 340.29 | 155.27 |
| Deferred Income Tax | 39.88 | 0 | 0 |
| Accounts Receivable-Trade Net | 829.67 | 780.2 | 642.54 |
| Property/Plant/Equipment Total-Net | 1,303.84 | 1,309.99 | 1,317.2 |
| Total Current Liabilities | 885.94 | 991.97 | 737.6 |
| Total Inventory | 980.97 | 993.23 | 744.28 |
| Accounts Payable | 356.63 | 402.55 | 351.26 |
| Other Currentliabilities Total | 72.12 | 197.75 | 178.62 |
| Total Long Term Debt | 65.12 | 86 | 62.38 |
| Intangibles Net | 7.33 | 18.7 | 56.36 |
| Other Long Term Assets Total | 39.78 | 65.81 | 38.05 |
| Note Receivable-Long Term | 178.99 | 135.59 | 112.54 |
| Unrealized Gain(Loss) | 14.7 | 14.7 | 44.2 |
| Total Current Assets | 2,197.34 | 2,029.47 | 1,743.32 |
| Capital Lease Obligations | 26 | 25.19 | 24.16 |
| Cash Equivalents | Not available | 0.79 | Not available |
Valuation and ratios
Valuation
PEG Ratio0.33
Price to Sale Ratio0.17
Growth
Debt 5Yr CAGR %33.24
Margins
Operating Margin 12m-0.66
Operating Margin 5y Avg-2.01
Net Profit Margin 12m11.48
Net Profit Margin 5y1.46
Yield
Dividend Yield %0
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk57.34
Recommendations
Target High685.95
Target Low280
Target Mean0
Target Median0
Analyst count, source and as-of date are not provided; target values should be treated as unverified.Peer comparison
Only peers present in the company profile payload are displayed.
| Symbol | Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|---|
| — | Aurobindo Pharma | INR 1,535.7 | 88,526.11 | 25.09 | — |
| — | Neuland Laboratories | INR 18,400 | 23,672.85 | 64.28 | — |
| — | Pfizer | INR 4,593 | 20,966.13 | 27.53 | — |
| — | Jagsonpal Pharmaceuticals | INR 222 | 1,456.38 | 34.27 | — |
| — | Themis Medicare | INR 110.2 | 1,015.38 | 632.19 | — |
Ownership
- Promoter
- 70.22%
- FII
- 0.90%
- MF
- 9.32%
- Other
- 19.56%
Events
- annual General MeetingAGM
- board MeetingsAudited Results
- annual General MeetingPOM
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- board MeetingsAudited Results
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- board MeetingsOthers
- board MeetingsQuarterly Results
- annual General MeetingAGM
- board MeetingsAudited Results
- annual General MeetingPOM
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- board MeetingsQuarterly Results
- board MeetingsAudited Results
- annual General MeetingPOM
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Stocks market today: Experts have recommended buying Unichem Laboratories, Torrent Power, Infosys, TVS Motor, and Apollo Hospitals.
Tata Chemicals, TVS Supply Chain Solutions, eMudhra, Fusion Micro Finance, Ideaforge Technology, Insecticides (India), Linde India, Unichem Laboratories, Varun Beverages, Vijaya Diagnostic Centre among others will also declare Q3 results today.
Companies such as Bandhan Bank, JSW Energy, Tata Steel Long Products, Unichem Laboratories and Just Dial will announce their Q1 results today.
JSW Energy, Bandhan Bank, CCL Products, Coromandel Engineering, Den Networks, GTPL Hathway, Just Dial, Kesoram Ind, Sastasundar Ventures, Tata Steel Long Products, Unichem Laboratories, Vandana Knitwear, and VST Industries are scheduled to announce their June quarter earnings today
Unichem laboratories reported a net loss of ₹ 44.4 crore in the April quarter of FY23. The company had reported a net consolidated profit of ₹ 71.5 crore in the April quarter of FY22
JSW Energy, Akzo Nobel India, Amara Raja Batteries, Ashok Leyland, Bajaj Electricals, Biocon, CMS Info Systems, Dishman Carbogen Amcis, Dixon Technologies (India), NMDC, TTK Healthcare, and Unichem Laboratories are among companies set to announce quarterly earnings today
This occurred following their decision to purchase a 33.38% stake in Unichem Laboratories
Business information
Unichem Laboratories Limited is an India-based international, integrated, specialty pharmaceutical company. The Company is focused on product development, process chemistry and manufacturing complex active pharmaceutical ingredients (API) as well as dosage forms. It manufactures and markets pharmaceutical formulations as branded generics as well as generics in several markets across the world. It has several pharma products that address the needs of various therapeutic areas, such as gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infectives and pain management. The Company is also engaged in contract manufacturing with the focus on immediate-release dosage forms, extended-release dosage forms: matrix and pellets, dry powder injections and syrups, novel drug delivery systems, and technology transfer and documentation. Its subsidiaries include Unichem Pharmaceuticals (USA) Inc, Unichem Farmaceutica Do Brasil Lta and Niche Generics Limited UK.
- Industry
- Major Drugs
- Sector
- Major Drugs
- Website
- Not available
- Address
- Not available
- NSE Code
- UNICHEMLAB
- BSE Code
- 506690
AI analysis
This repository contains no authenticated model-inference API, model version, confidence distribution or forecast timestamp. The Android listing is available; verify report availability, entitlement and pricing inside the app.
Open Google PlayStock FAQ
What is the symbol and ISIN of Unichem Laboratories?
Unichem Laboratories has the symbol UNICHEMLAB and ISIN - INE351A01035.
What is the current price of Unichem Laboratories?
Unichem Laboratories is currently trading at INR 541.65.
What are the year high and year low of Unichem Laboratories?
Unichem Laboratories has a year high of INR 685.95 and a year low of INR 280.00.
What is the market capitalization of Unichem Laboratories?
Unichem Laboratories has a market capitalization of INR 3,811.42 crore.
What is the P/E ratio of Unichem Laboratories?
Unichem Laboratories has a P/E ratio of 8.17.
What is the dividend yield of Unichem Laboratories?
Unichem Laboratories has a dividend yield of 0.00%.
How is the financial performance of Unichem Laboratories based on revenue, net income, and EPS?
Unichem Laboratories has revenue of INR 22,018.50 crore, net income of INR 2,528.40 crore, and EPS of INR 7.69.
What is the book value of Unichem Laboratories?
Unichem Laboratories has a book value of INR 384.71.
What is the debt-to-equity ratio of Unichem Laboratories?
Unichem Laboratories has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Unichem Laboratories?
Unichem Laboratories has a price-to-book ratio of 1.41 and a price-to-sales ratio of 0.17.
Corporate-action adjustment is provider-defined. ShareKeyX research and computed indicators are not investment advice.
